A Phase 4 interventional study of NPH insulin and Glargine and Lispro insulin in Type 2 Diabetes Mellitus, sponsored by Universidad de Guanajuato. Completed at 1 site in Mexico. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by Universidad de Guanajuato · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, 1 of them phase 3. Insulin, Isophane · Diabetes Mellitus, Type 2.
Among the 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 4, and was the 15th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Loyola University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 5
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 125 across the 17 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 9 most frequent:
Universidad de Guanajuato is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Universidad de Guanajuato has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
1 of the studies testing Insulin, Isophane in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07757464Shifa International HospitalPre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing Insulin, Isophane in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to determine differences in glycemic control between a basal-bolus scheme insulin and NPH scheme insulin in a population of hospitalized patients with type 2 diabetes in a Noncritical Care Facility in Mexico. Patients with a recent diagnosis of type 2 and patients on treatment with oral hypoglycaemic agents and insulin or only insulin were included.
The primary outcome of the study is to determine difference in efficacy and security between a basal-bolus scheme insulin and NPH scheme insulin in patients with type 2 diabetes hospitalized in non-critical areas in a hospital in Mexico
On the first 4 to 6 h, the use of NPH insulin present a pronounced action peak on the postprandial glucose metabolism, and the rest of its basal action last 12 to 18 h, its cover the postprandial requirements of the first two meals of the day (breakfast and lunch) administering 2/3 of the total dose, and the requirements for the dinner with 1/3 of the total dose at the night. This is considered a good scheme for handling hyperglycemia, and its possible to have less hypoglycemia episodes, which are possible if an ultra-rapid-acting insulin is added and adequate intake is not performed due to multiple factors related to hospitalization.
Today it is uncertain whether there is any clear benefit of using Glargine plus Lantus insulin over NPH insulin in hospitalized patients with type 2 diabetes. Currently, both Glargine and NPH based regimen is practiced in inpatient hospital facilities. Current practice of inpatient insulin regimen is based on the physicians familiarity with a particular insulin type and personal preference rather than evidenced based knowledge. Glargine plus ultrafast insulin are two types of insulin that are more expensive compared to NPH with incidental benefits in hospitalized patients. There are reports in the literature about the incidence of hypoglycemia with this scheme. The current research proposal is to compare these two schemes in the treatment of hospitalized patients with diabetes in a hospital of the second level of care in Mexico.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
Drug: NPH insulin
Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro. Intervention drug: Glargine and Lispro
Drug: Glargine and Lispro insulin
NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
Also known as: NPH
Drug pages: Insulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Insulin LisproStudies of Insulin LisproInsulin Lispro pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
Also known as: Glargine and Lispro
Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin.
To determine the differences in the mean daily blood glucose measured in mg/dl, between a basal-bolus scheme and NPH schemes of insulin measured by the mean daily blood glucose.
Time frame: Fasting blood glucose was taken every day, before breakfast, up to 4 weeks; postprandial glucose was taken every day, 2 hours after breakfast, 2 hours after lunch, and 2 hours after dinner, up to 4 weeks; glucose early morning was taken 3 am, up to 4 week
the Number of Participants With Mild and Severe Hypoglycemic Events
To measure the number of participants with mild and severe hypoglycemic events
Time frame: Duration of hospital stay, up to 4 weeks.
Number of Participants With Sustained Glycemic Control During Hospital Stay
Sustained glycemic control were the number of participants who not had: discharged before sustained control, critical status suspension, death before control, bad attachment to the protocol, interruption due to more than 2 hypoglycemic events during their hospital stay.
Time frame: blood glucose was taken every day, up to 4 weeks.
A total of 111 hospitalized DM2 patients not critical to the study were evaluated. Of these, 35 did not meet the inclusion criteria and the 75 included participants were randomized into two groups. The recruitment of patients began on November 2, 2017 and ended on June 1, 2018.
| Milestone | NPH Insulin Group | Glargine and Lispro Insulin Group |
|---|---|---|
| Started | 39 | 36 |
| Completed | 31 | 28 |
| Not completed | 8 | 8 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
To determine the differences in the mean daily blood glucose measured in mg/dl, between a basal-bolus scheme and NPH schemes of insulin measured by the mean daily blood glucose.
| mg/dl | NPH Insulin Group | Glargine and Lispro Insulin Group |
|---|---|---|
| Fasting blood glucose | 129.6 ± 23.6 | 135 ± 22.6 |
| Postprandial glucose | 155.4 ± 29 | 156.2 ± 27.2 |
| Glucose in the early morning | 127.4 ± 26.6 | 136.2 ± 21.2 |
To measure the number of participants with mild and severe hypoglycemic events
| Participants | NPH Insulin Group | Glargine and Lispro Insulin Group |
|---|---|---|
| the Number of Participants With Mild and Severe Hypoglycemic Events | 15 | 15 |
Sustained glycemic control were the number of participants who not had: discharged before sustained control, critical status suspension, death before control, bad attachment to the protocol, interruption due to more than 2 hypoglycemic events during their hospital stay.
| Participants | NPH Insulin Group | Glargine and Lispro Insulin Group |
|---|---|---|
| Number of Participants With Sustained Glycemic Control During Hospital Stay | 30 | 20 |
Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NPH Insulin Group | 1/39 (2.6%) | 0/39 (0%) | 15/39 (38.5%) |
| Glargine and Lispro Insulin Group | 1/36 (2.8%) | 0/36 (0%) | 11/36 (30.6%) |
| Event | NPH Insulin Group | Glargine and Lispro Insulin Group |
|---|---|---|
| Soft tissue infectionInfections and infestations | 14/39 | 9/36 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/39 | 1/36 |
| Acute renal failureRenal and urinary disorders | 0/39 | 1/36 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/39 | 0/36 |
| Age, Categorical(Participants) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 27 | 52 |
| >=65 years | 14 | 9 | 23 |
| Age, Continuous(years) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| Mean | 59 ± 13.1 | 56.4 ± 12.9 | 57.8 ± 13 |
| Sex: Female, Male(Participants) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| Female | 20 | 21 | 41 |
| Male | 19 | 15 | 34 |
| Ethnicity (NIH/OMB)(Participants) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 36 | 75 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| Mexico | 39 | 36 | 75 |
| Central glucose(mg / dl) | NPH Insulin Group | Glargine and Lispro Insulin Group | Total |
|---|---|---|---|
| Mean | 237.3 ± 73.1 | 223.1 ± 67 | 230.5 ± 70.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Jul 2018, 7 months.
Results were first posted in Jan 2020, 1 year 6 months after primary completion.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 7 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Isophane
Universidad de Guanajuato